Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Accounts Payables (2024 - 2025)

Evommune (EVMN) has disclosed Accounts Payables for 2 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 6.15% to $7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.8 million, a 6.15% decrease, with the full-year FY2025 number at $7.8 million, down 6.15% from a year prior.
  • Accounts Payables was $7.8 million for Q4 2025 at Evommune, up from $3.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.3 million in Q4 2024 to a low of $3.6 million in Q3 2025.